SCHEMBL14966820

SCHEMBL14966820

Cc1cc(C)c(CNC(=O)c2ccc(Oc3ccccc3)c(C)c2)c(O)n1

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.47
MAPT P10636 1/20 0.47
MAPK14 Q16539 4/20 0.47
LMNA P02545 3/20 0.46
KLKB1 P03952 4/20 0.44
CYP3A4 P08684 1/20 0.41
HTT P42858 1/20 0.41
MMP13 P45452 1/20 0.41
ALDH1A1 P00352 2/20 0.41
KDM4E B2RXH2 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
NR1H4 Q96RI1 2/20 0.41
HPGD P15428 1/20 0.41
PKM P14618 1/20 0.40
APP P05067 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14967422 0.89 MAPK14 (0.56) SMN1; SMN2MAPK14LMNAKLKB1CYP3A4
SCHEMBL14967480 0.87 SMN1; SMN2 (0.43) SMN1; SMN2MAPTMAPK14LMNAKLKB1
SCHEMBL14967126 0.83 LMNA (0.46) SMN1; SMN2MAPTLMNAKLKB1ALDH1A1
SCHEMBL14967238 0.83 KLKB1 (0.44) SMN1; SMN2MAPK14LMNAKLKB1CYP3A4
SCHEMBL14967045 0.82 SMN1; SMN2 (0.41) SMN1; SMN2MAPTLMNAKLKB1ALDH1A1
SCHEMBL14966826 0.82 SMN1; SMN2 (0.41) SMN1; SMN2MAPTLMNAKLKB1ALDH1A1
SCHEMBL14966646 0.82 KLKB1 (0.46) SMN1; SMN2MAPK14LMNAKLKB1CYP3A4
SCHEMBL14966827 0.82 SMN1; SMN2 (0.43) SMN1; SMN2MAPTLMNAKLKB1HTT
SCHEMBL14966648 0.81 MAPK14 (0.61) SMN1; SMN2MAPK14LMNAKLKB1CYP3A4
SCHEMBL14966854 0.81 LMNA (0.61) SMN1; SMN2MAPTMAPK14LMNAKLKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9206128-B2 Modulators of methyl modifying enzymes, compositions and uses thereof CONSTELLATION PHARMACEUTICALS, INC. (US) 2015-12-08 US disclosed
US-9206128-B2 Modulators of methyl modifying enzymes, compositions and uses thereof CONSTELLATION PHARMACEUTICALS, INC. (US) 2015-12-08 US disclosed
US-9206128-B2 Modulators of methyl modifying enzymes, compositions and uses thereof CONSTELLATION PHARMACEUTICALS, INC. (US) 2015-12-08 US disclosed
US-20140288123-A1 MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF CONSTELLATION PHARMACEUTICALS, INC. 2014-09-25 US disclosed
EP-2780014-A1 MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF Constellation Pharmaceuticals, Inc. (US) 2014-09-24 EP disclosed
WO-2013075083-A1 MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF CONSTELLATION PHARMACEUTICALS (US) 2013-05-23 WO disclosed
WO-2013075083-A1 MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF CONSTELLATION PHARMACEUTICALS (US) 2013-05-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140288123-A1 MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF TET1, TET3, EHMT2 SMN1; SMN2 3191/4885MAPT 3877/4885MAPK14 4092/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.